For the year ending 2025-12-31, IGC made $869K in revenue. -$4,186K in net income. Net profit margin of -481.70%.
| Income Statement | 2025-12-31 | 2025-03-31 | ||
|---|---|---|---|---|
| Revenue | 869 | 1,271 | ||
| Cost of revenue | 572 | 652 | ||
| Selling, general, and administrative expenses | 4,121 | 4,410 | ||
| Research and development expenses | 3,921 | 3,655 | ||
| Operating loss | -7,745 | -7,446 | ||
| Other income, net | 3,599 | 325 | ||
| Loss before income taxes | -4,146 | -7,121 | ||
| Income tax expense | 0 | - | ||
| Net loss attributable to common stockholders | -4,146 | -7,121 | ||
| Foreign currency translation adjustments | -40 | -30 | ||
| Comprehensive loss | -4,186 | -7,151 | ||
| Basic EPS | -0.05 | -0.09 | ||
| Diluted EPS | -0.05 | -0.09 | ||
| Basic Average Shares | 88,851,556 | 76,517,175 | ||
| Diluted Average Shares | 88,851,556 | 76,517,175 | ||
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)